CURRENT PUBLICATIONS
LABORATORY RESEARCH
Interaction of E-cadherin and PTEN Regulates Morphogenesis and Growth Arrest in Human Mammary Epithelial Cells
E-cadherin regulates both the PTEN protein levels and its recruitment to cell-cell junctions in three-dimensional lrECM, indicating a dynamic reciprocity between architectural integrity and the levels and localization of PTEN. [Cancer Res]
PI-3 Kinase Activity is Necessary for ERK1/2 Induced Disruption of Mammary Epithelial Architecture
ERK1/2 activation is sufficient to induce cell behaviors in organotypic culture that could promote recurrent and invasive growth in DCIS patients. Interestingly, PI-3K activity is necessary for two of these behaviors, proliferation and cell motility. [Breast Cancer Res]
Development of Mammary Tumors by Conditional Expression of GLI1
The data strongly support a role of Hh/GLI signaling in breast cancer development and suggest that inhibition of this signaling pathway represents a new therapeutic opportunity for limiting tumorigenesis and early tumorigenic progression. [Cancer Res]
Links between Transforming Growth Factor-Beta and Canonical Wnt Signaling Yield New Insights into Breast Cancer Susceptibility, Suppression and Tumor Heterogeneity
Scientists show that inhibition of stromal TGF-beta signaling or Wnt5a loss leads to increased beta-catenin transcriptional activity and reduced latency in mammary tumor models, with tumors displaying a higher proportion of progenitor cell markers. [Breast Cancer Res]
Artemin is Oncogenic for Human Mammary Carcinoma Cells
Depletion of endogenous artemin with small interfering RNA, or antibody inhibition of artemin, decreases the oncogenicity and invasiveness of mammary carcinoma cells. [Oncogene]
Cell Surface Profiling with Peptide Libraries Yields Ligand Arrays that Classify Breast Tumor Subtypes
Cell surface profiling using highly specific breast tumor cell binding ligands may provide an efficient route for tumor subtype classification, biomarker identification, and for the development of targeted diagnostics and therapeutics. [Mol Cancer Ther]
The Nonsteroidal Anti-Inflammatory Drug Tolfenamic Acid Inhibits BT474 and SKBR3 Breast Cancer Cell and Tumor Growth by Repressing erbB2 Expression
Tolfenamic acid represents a novel and promising new anticancer drug that targets erbB2 by decreasing transcription of this oncogene. [Mol Cancer Ther]
CLINICAL RESEARCH
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, as Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
Incorporating paclitaxel into anthracycline-based adjuvant therapy resulted in a significant improvement in RFS and distant RFS. [J Clin Oncol]
Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer
Although LRF is uncommon in patients with node-negative breast cancer who are treated with lumpectomy, radiation, and adjuvant systemic therapy, those who do develop LRF have substantially worse OS and DDFI. [J Clin Oncol]
Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
Standard adjuvant chemotherapy is superior to capecitabine in patients with early-stage breast cancer who are 65 years of age or older. [N Engl J Med]
Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2
Researchers evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2. [N Engl J Med]
Sequential Docetaxel as Adjuvant Chemotherapy for Early Breast Cancer (TACT): an Open-Label, Phase III, Randomised Controlled Trial
This study did not show any overall gain from the addition of docetaxel to standard anthracycline chemotherapy. Exploration of predictive biomarker-defined subgroups might have the potential to better target the use of taxane-based therapy. [Lancet Oncol]
Ki67 Index, HER2 Status, and Prognosis of Patients with Luminal B Breast Cancer
Expression of ER, progesterone receptor, and HER2 proteins and the Ki67 index appear to distinguish luminal A from luminal B breast cancer subtypes. [J Natl Cancer Inst]
|
